NO20080408L - Azaindazolforbindelser og anvendelse derav - Google Patents

Azaindazolforbindelser og anvendelse derav

Info

Publication number
NO20080408L
NO20080408L NO20080408A NO20080408A NO20080408L NO 20080408 L NO20080408 L NO 20080408L NO 20080408 A NO20080408 A NO 20080408A NO 20080408 A NO20080408 A NO 20080408A NO 20080408 L NO20080408 L NO 20080408L
Authority
NO
Norway
Prior art keywords
compounds
ccr1
antagonists
azaindazole compounds
assays
Prior art date
Application number
NO20080408A
Other languages
English (en)
Other versions
NO340621B1 (no
Inventor
Penglie Zhang
Andrew M K Penneli
John J Kim Wright
Wei Chen
Manmohan R Leleti
Yandong Li
Lianfa Li
Yuan Xu
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37595833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080408(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of NO20080408L publication Critical patent/NO20080408L/no
Publication of NO340621B1 publication Critical patent/NO340621B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det er tilveiebrakt forbindelser som virker som potente antagonister av CCR1-reseptorer, og som har antiinflammatorisk aktivitet in vivo. Forbindelsene er generelt arylpiperazinderivater med formel Ia/Ib og er nyttige i farmasøytiske preparater, metoder for behandling av CCR1-medierte sykdommer og som kontroller i analyser for identifisering av kompetitive CCR1-antagonister.
NO20080408A 2005-06-22 2008-01-21 Azaindazolforbindelser, farmasøytiske preparater derav og anvendelse derav NO340621B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69352505P 2005-06-22 2005-06-22
PCT/US2006/024313 WO2007002293A2 (en) 2005-06-22 2006-06-22 Azaindazole compounds and methods of use

Publications (2)

Publication Number Publication Date
NO20080408L true NO20080408L (no) 2008-03-25
NO340621B1 NO340621B1 (no) 2017-05-15

Family

ID=37595833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080408A NO340621B1 (no) 2005-06-22 2008-01-21 Azaindazolforbindelser, farmasøytiske preparater derav og anvendelse derav

Country Status (26)

Country Link
US (2) US7524845B2 (no)
EP (1) EP1906965B1 (no)
JP (1) JP5275794B2 (no)
KR (2) KR20140026644A (no)
CN (1) CN101242839B (no)
AU (1) AU2006262122B2 (no)
BR (1) BRPI0612112A8 (no)
CA (1) CA2612552C (no)
DK (1) DK1906965T3 (no)
EA (1) EA017278B9 (no)
ES (1) ES2543714T3 (no)
HR (1) HRP20150832T1 (no)
HU (1) HUE025476T2 (no)
IL (1) IL188050A (no)
MA (1) MA29568B1 (no)
MX (1) MX2007015917A (no)
NO (1) NO340621B1 (no)
NZ (1) NZ564258A (no)
PL (1) PL1906965T3 (no)
PT (1) PT1906965E (no)
RS (1) RS54206B1 (no)
SG (2) SG10201504801VA (no)
SI (1) SI1906965T1 (no)
UA (1) UA95777C2 (no)
WO (2) WO2007002667A2 (no)
ZA (2) ZA200800309B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
BRPI0612112A8 (pt) 2005-06-22 2017-12-26 Chemocentryx Inc composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
US20090252779A1 (en) * 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
DK2155712T3 (en) 2007-05-22 2016-12-19 Chemocentryx Inc 3- (imidazolyl) pyrazolo [3,4-b] pyridines
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5654467B2 (ja) 2008-09-11 2015-01-14 ケモセントリックス，インコーポレイティド ４−アミノ−３−（イミダゾリル）−ピラゾロ［３，４−ｄ］ピリミジン
EP2346868B1 (en) 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
GEP20135879B (en) * 2009-08-03 2013-07-10 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2491028B1 (en) * 2009-10-21 2013-12-11 Boehringer Ingelheim International GmbH Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
LT3181133T (lt) 2010-12-20 2019-09-25 Pfizer Inc. Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
GB2488752A (en) * 2011-02-21 2012-09-12 Sony Dadc Austria Ag Microfluidic Device
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
EP2755974A1 (en) 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA030067B1 (ru) 2013-07-22 2018-06-29 Идорсиа Фармасьютиклз Лтд Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105801574A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种1H-吡唑并[3,4-b]吡啶化合物的制备方法
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
JP6337218B2 (ja) 2015-01-15 2018-06-06 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｃｘｃｒ３受容体調節剤としてのヒドロキシアルキル−ピペラジン誘導体
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CN109310677A (zh) * 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN108570049A (zh) * 2018-07-24 2018-09-25 上海毕得医药科技有限公司 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
JP7667097B2 (ja) * 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
CN110343103A (zh) * 2019-07-04 2019-10-18 深圳市格物致欣化学技术有限公司 吡唑并吡啶类化合物及其制备方法
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AR129722A1 (es) * 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU517350B2 (en) 1977-10-26 1981-07-23 Wellcome Foundation Limited, The Imidazoline derivatives
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4927942A (en) 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
EP1309593B1 (en) * 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
CA2463272C (en) * 2001-10-22 2009-11-17 Laura Cook Blumberg Piperazine derivatives with ccr1 receptor antagonist activity
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
BRPI0612112A8 (pt) 2005-06-22 2017-12-26 Chemocentryx Inc composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.

Also Published As

Publication number Publication date
WO2007002293A2 (en) 2007-01-04
SG162807A1 (en) 2010-07-29
EP1906965A4 (en) 2011-05-18
PT1906965E (pt) 2015-09-03
BRPI0612112A2 (pt) 2010-10-19
SG10201504801VA (en) 2015-07-30
NO340621B1 (no) 2017-05-15
ES2543714T3 (es) 2015-08-21
PL1906965T3 (pl) 2015-10-30
HK1124241A1 (en) 2009-07-10
MX2007015917A (es) 2008-03-10
SI1906965T1 (sl) 2015-09-30
ZA200800309B (en) 2009-10-28
HUE025476T2 (en) 2016-02-29
US20070010524A1 (en) 2007-01-11
JP2008546794A (ja) 2008-12-25
HRP20150832T1 (hr) 2015-09-25
IL188050A (en) 2015-10-29
WO2007002667A3 (en) 2007-05-10
WO2007002293A3 (en) 2007-03-08
WO2007002667A2 (en) 2007-01-04
CA2612552A1 (en) 2007-01-04
US20070010523A1 (en) 2007-01-11
CN101242839B (zh) 2012-11-07
KR20140026644A (ko) 2014-03-05
EA200800100A1 (ru) 2008-06-30
MA29568B1 (fr) 2008-06-02
DK1906965T3 (en) 2015-08-03
EA017278B1 (ru) 2012-11-30
EP1906965A2 (en) 2008-04-09
NZ564258A (en) 2011-02-25
ZA200901845B (en) 2011-03-30
CN101242839A (zh) 2008-08-13
RS54206B1 (sr) 2015-12-31
BRPI0612112A8 (pt) 2017-12-26
EA017278B9 (ru) 2013-01-30
CA2612552C (en) 2015-03-24
JP5275794B2 (ja) 2013-08-28
KR101418024B1 (ko) 2014-07-16
AU2006262122A1 (en) 2007-01-04
IL188050A0 (en) 2008-03-20
UA95777C2 (en) 2011-09-12
US7524845B2 (en) 2009-04-28
KR20080039850A (ko) 2008-05-07
EP1906965B1 (en) 2015-05-06
AU2006262122B2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
EP2155203A4 (en) Azaindazole compounds and methods of use
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
UY30500A1 (es) Compuestos de azabencimidazolilo
EA200901583A1 (ru) N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
WO2007073432A3 (en) Piperidine derivatives and methods of use
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
ECSP077277A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees